Sang Won Seo1, Marie-Pierre Thibodeau1, David C Perry1, Alice Hua1, Manu Sidhu1, Isabel Sible1, Jose Norberto S Vargas1, Stephanie E Gaus1, Gil D Rabinovici1, Katherine D Rankin1, Adam L Boxer1, Joel H Kramer1, Howard J Rosen1, Maria Luisa Gorno-Tempini1, Lea T Grinberg1, Eric J Huang1, Stephen J DeArmond1, John Q Trojanowski1, Bruce L Miller1, William W Seeley2. 1. From the Memory and Aging Center, Department of Neurology (S.W.S., D.C.P., A.H., M.S., I.S., J.N.S.V., S.E.G., G.R., K.D.R., A.L.B., J.H.K., H.J.R., M.L.G.-T., L.T.G., B.L.M., W.W.S.), and Department of Pathology (L.T.G., E.J.H., S.J.D., W.W.S.), University of California, San Francisco; Department of Neurology (S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Geriatrics (M.-P.T.), Centre Hospitalier de l'Université de Montréal, University of Montreal, Canada; and Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research and Institute on Aging (J.Q.T.), University of Pennsylvania, Philadelphia. 2. From the Memory and Aging Center, Department of Neurology (S.W.S., D.C.P., A.H., M.S., I.S., J.N.S.V., S.E.G., G.R., K.D.R., A.L.B., J.H.K., H.J.R., M.L.G.-T., L.T.G., B.L.M., W.W.S.), and Department of Pathology (L.T.G., E.J.H., S.J.D., W.W.S.), University of California, San Francisco; Department of Neurology (S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Geriatrics (M.-P.T.), Centre Hospitalier de l'Université de Montréal, University of Montreal, Canada; and Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research and Institute on Aging (J.Q.T.), University of Pennsylvania, Philadelphia. wseeley@memory.ucsf.edu.
Abstract
OBJECTIVE: To examine clinicopathologic correlations in early vs late age at onset frontotemporal dementia (FTD) and frontotemporal lobar degeneration (FTLD). METHODS: All patients were clinically evaluated and prospectively diagnosed at the UCSF Memory and Aging Center. Two consecutive series were included: (1) patients with a clinically diagnosed FTD syndrome who underwent autopsy (cohort 1) and (2) patients with a primary pathologic diagnosis of FTLD, regardless of the clinical syndrome (cohort 2). These series were divided by age at symptom onset (cutoff 65 years). RESULTS: In cohort 1, 48 (25.3%) were 65 years or older at symptom onset. Pathologic causes of behavioral variant FTD (bvFTD) were similar in the early age at onset (EO) and late age at onset (LO) bvFTD groups. In corticobasal syndrome (CBS), however, the most common pathologic substrate differed according to age at onset: progressive supranuclear palsy (42.9%) in LO-CBS and Alzheimer disease (AD; 40.7%) in EO-CBS. In cohort 2, 57 (28.4%) were classified as LO-FTLD. Regarding FTLD major molecular classes, FTLD with transactive response DNA-binding protein of 43 kDa was most common in EO-FTLD (44.4%), whereas FTLD-tau (58.3%) was most common in LO-FTLD. Antemortem diagnosis of a non-FTD syndrome, usually AD-type dementia, was more frequent in LO-FTLD than EO-FTLD (19.3% vs 7.7%, p = 0.017). LO-FTLD was also associated with more prevalent comorbid pathologic changes. Of these, moderate to severe AD neuropathologic change and argyrophilic grain disease were overrepresented among patients who received an antemortem diagnosis of AD-type dementia. CONCLUSION: Patients with FTD and FTLD often develop symptoms after age 65, and age at onset represents an important consideration when making antemortem neuropathologic predictions.
OBJECTIVE: To examine clinicopathologic correlations in early vs late age at onset frontotemporal dementia (FTD) and frontotemporal lobar degeneration (FTLD). METHODS: All patients were clinically evaluated and prospectively diagnosed at the UCSF Memory and Aging Center. Two consecutive series were included: (1) patients with a clinically diagnosed FTD syndrome who underwent autopsy (cohort 1) and (2) patients with a primary pathologic diagnosis of FTLD, regardless of the clinical syndrome (cohort 2). These series were divided by age at symptom onset (cutoff 65 years). RESULTS: In cohort 1, 48 (25.3%) were 65 years or older at symptom onset. Pathologic causes of behavioral variant FTD (bvFTD) were similar in the early age at onset (EO) and late age at onset (LO) bvFTD groups. In corticobasal syndrome (CBS), however, the most common pathologic substrate differed according to age at onset: progressive supranuclear palsy (42.9%) in LO-CBS and Alzheimer disease (AD; 40.7%) in EO-CBS. In cohort 2, 57 (28.4%) were classified as LO-FTLD. Regarding FTLD major molecular classes, FTLD with transactive response DNA-binding protein of 43 kDa was most common in EO-FTLD (44.4%), whereas FTLD-tau (58.3%) was most common in LO-FTLD. Antemortem diagnosis of a non-FTD syndrome, usually AD-type dementia, was more frequent in LO-FTLD than EO-FTLD (19.3% vs 7.7%, p = 0.017). LO-FTLD was also associated with more prevalent comorbid pathologic changes. Of these, moderate to severe AD neuropathologic change and argyrophilic grain disease were overrepresented among patients who received an antemortem diagnosis of AD-type dementia. CONCLUSION: Patients with FTD and FTLD often develop symptoms after age 65, and age at onset represents an important consideration when making antemortem neuropathologic predictions.
Authors: Helen Ling; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Luke A Massey; David R Williams; Dominic C Paviour; Andrew J Lees Journal: Brain Date: 2010-07 Impact factor: 13.501
Authors: Julene K Johnson; Janine Diehl; Mario F Mendez; John Neuhaus; Jill S Shapira; Mark Forman; Dennis J Chute; Erik D Roberson; Catherine Pace-Savitsky; Manuela Neumann; Tiffany W Chow; Howard J Rosen; Hans Forstl; Alexander Kurz; Bruce L Miller Journal: Arch Neurol Date: 2005-06
Authors: D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs Journal: Acta Neuropathol Date: 2010-05-20 Impact factor: 17.088
Authors: Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2009-11-19 Impact factor: 17.088
Authors: Ignacio Illán-Gala; Victor Montal; Sergi Borrego-Écija; Eduard Vilaplana; Jordi Pegueroles; Daniel Alcolea; Belén Sánchez-Saudinós; Jordi Clarimón; Janina Turón-Sans; Nuria Bargalló; Sofía González-Ortiz; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Albert Lladó; Ricard Rojas-García; Rafael Blesa; Raquel Sánchez-Valle; Alberto Lleó; Juan Fortea Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Lucia A A Giannini; Claire Peterson; Daniel Ohm; Sharon X Xie; Corey T McMillan; Katya Raskovsky; Lauren Massimo; EunRah Suh; Vivianna M Van Deerlin; David A Wolk; John Q Trojanowski; Edward B Lee; Murray Grossman; David J Irwin Journal: Acta Neuropathol Commun Date: 2021-02-23 Impact factor: 7.801
Authors: Jay L P Fieldhouse; Flora T Gossink; Thomas C Feenstra; Sterre C M de Boer; Afina W Lemstra; Niels D Prins; Femke Bouwman; Ted Koene; Hanneke F M Rhodius-Meester; Freek Gillissen; Charlotte E Teunissen; Wiesje M van der Flier; Philip Scheltens; Annemieke Dols; Everard G B Vijverberg; Yolande A L Pijnenburg Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Shelley L Forrest; Glenda M Halliday; Heather McCann; Andrew B McGeachie; Ciara V McGinley; John R Hodges; Olivier Piguet; John B Kwok; Maria G Spillantini; Jillian J Kril Journal: Alzheimers Dement (Amst) Date: 2019-01-24
Authors: Qun Yu; Yingren Mai; Yuting Ruan; Yishan Luo; Lei Zhao; Wenli Fang; Zhiyu Cao; Yi Li; Wang Liao; Songhua Xiao; Vincent C T Mok; Lin Shi; Jun Liu Journal: Alzheimers Res Ther Date: 2021-01-12 Impact factor: 6.982
Authors: Ignacio Illán-Gala; Salvatore Nigro; Lawren VandeVrede; Neus Falgàs; Hilary W Heuer; Cèlia Painous; Yaroslau Compta; Maria J Martí; Victor Montal; Javier Pagonabarraga; Jaime Kulisevsky; Alberto Lleó; Juan Fortea; Giancarlo Logroscino; Andrea Quattrone; Aldo Quattrone; David C Perry; Maria Luisa Gorno-Tempini; Howard J Rosen; Lea T Grinberg; Salvatore Spina; Renaud La Joie; Gil D Rabinovici; Bruce L Miller; Julio C Rojas; William W Seeley; Adam L Boxer Journal: JAMA Netw Open Date: 2022-04-01